S. Rodig
Computer Vision and Pattern Recognition · 2007–2020
A researcher in the Science corpus: 26 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Computer Vision and Pattern Recognition — 17 citations into it
Whom S. Rodig trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from S. Rodig's perspective
Ordered by how strongly the researchers S. Rodig trusts endorse each paper. Same corpus, a different order for every researcher.
- Representation Learning with Contrastive Predictive Coding
- Image-to-Image Translation with Conditional Adversarial Networks
- Multimodal Deep Learning
- Semi-Supervised Classification with Graph Convolutional Networks (International Conference on Learning Representations)
- ImageNet classification with deep convolutional neural networks
- Deep Residual Learning for Image Recognition (Computer Vision and Pattern Recognition)
- Inductive Representation Learning on Large Graphs (Neural Information Processing Systems)
- Adam: A Method for Stochastic Optimization (International Conference on Learning Representations)
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer (Nature)
- Self-Normalizing Neural Networks
Their papers
- Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells (2011) — 782 citations
- An immunogenic personal neoantigen vaccine for patients with melanoma (2017) — 2,625 citations
- Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma (2013) — 694 citations
- Comprehensive analyses of tumor immunity: implications for cancer immunotherapy (2016) — 2,015 citations
- A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors (2011) — 620 citations
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020) — 482 citations
- Cooperation between Constitutive and Inducible Chemokines Enables T-cell Engraftment and Immune Attack in Solid Tumors (2019) — 719 citations
- Pathomic Fusion: An Integrated Framework for Fusing Histopathology and Genomic Features for Cancer Diagnosis and Prognosis (2019) — 654 citations
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018) — 1,215 citations
- Molecular Subtypes of Diffuse Large B-cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and Outcomes (2018) — 1,686 citations
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (2016) — 1,425 citations
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. (2016) — 938 citations
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. (2016) — 701 citations
- Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study (2016) — 762 citations
- Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. (2015) — 630 citations
- Ibrutinib in previously treated Waldenström's macroglobulinemia. (2015) — 875 citations
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (2014) — 3,318 citations
- PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies (2013) — 789 citations
- Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors (2013) — 1,183 citations
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Post-transplant Lymphoproliferative Disorders: Implications for Targeted Therapy (2012) — 661 citations